RxDoctor Payments Data

Brent McQueen, MD

Ophthalmology · Liberty, TXNPI 1043216534

Payments from drug & device makers

$1,853in general payments, 2019–2025

Across 73 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$840
  • Glaukos Corporation$298
  • Alcon$173
  • Bausch & Lomb Americas Inc.$129
  • Omeros Corporation$79
  • Carl Zeiss Meditec, Inc.$72
  • plus $262 from 9 others

What the payments were for

  • Food & beverage$1,853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,853 in reported general payments places this provider in the 45th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$278,668
Medicare patients
664
Services billed
1,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost156$80,065
RestasisCyclosporine60$61,728
Cyclosporine46$25,542
VyzultaLatanoprostene Bunod16$9,322
Alphagan PBrimonidine Tartrate27$8,902
Latanoprost341$5,832
Travoprost29$5,399
Brimonidine Tartrate132$4,675
Bromfenac Sodium32$3,749
Lotemax SmLoteprednol Etabonate14$3,430
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$3,354
Prednisolone Acetate86$3,263
Fluorometholone52$3,073
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat89$1,876
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha180$1,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$840$150,695243 claims
Bausch & Lomb Americas Inc.Vyzulta$129$9,32216 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$21$3,43014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Liberty

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →